Anzeige
Mehr »
Dienstag, 10.03.2026 - Börsentäglich über 12.000 News
Das Triple-Discovery-Setup, das der Markt noch nicht begriffen hat!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DNC4 | ISIN: CA4838092084 | Ticker-Symbol: N/A
1-Jahres-Chart
KANE BIOTECH INC Chart 1 Jahr
5-Tage-Chart
KANE BIOTECH INC 5-Tage-Chart

Aktuelle News zur KANE BIOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
12:30Kane Biotech Inc.: Kane Biotech Expands U.S. Commercial Footprint with Strategic Distribution Partnership1
20.02.Kane Biotech Inc (2): Kane publishes article in International Wound Journal3
20.02.Kane Biotech Inc.: Kane Biotech Announces Publication of revyve Wound Gel Article in the International Wound Journal1
KANE BIOTECH Aktie jetzt für 0€ handeln
19.02.Kane Biotech Inc (2): Kane Biotech adds U.S. distributors for revyve products1
19.02.Kane Biotech Inc.: Kane Biotech Expands Commercial Activities in the United States686WINNIPEG, Manitoba, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) ("Kane Biotech" or the "Company") today announces that it has signed non-exclusive distribution/sales agreements...
► Artikel lesen
17.02.Kane Biotech Inc (2): Kane Biotech passes regulatory "milestones"1
17.02.Kane Biotech Inc.: Kane Biotech Announces FDA 510(k) Clearance for revyve Antimicrobial Skin and Wound Cleanser469WINNIPEG, Manitoba, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSXV:KNE) ("Kane Biotech". "Kane" or the "Company") today announces two regulatory milestones that strengthen the Company's...
► Artikel lesen
12.02.Kane Biotech Inc (2): Kane Biotech revives commercial activity for revyve gel1
12.02.Kane Biotech Inc.: Kane Biotech Restarts Commercial Activities and Strengthens North American Management354WINNIPEG, Manitoba, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) ("Kane Biotech", "Kane" or the "Company") today announces the resumption of commercial activities in both the United...
► Artikel lesen
30.12.25Kane Biotech Inc (2): Kane Biotech 14-million-share private placement2
18.12.25Kane Biotech Inc.: Kane Biotech Announces Closing of Private Placement Offering with an Insider of the Company1
17.12.25Kane Biotech Inc.: Kane Biotech Presents New Data at Innovations in Wound Healing Annual Meeting1
10.12.25Kane Biotech Inc.: Kane Biotech Receives Health Canada Approval for revyve Antimicrobial Wound Gel Spray1
28.11.25Kane Biotech Inc (2): Kane Biotech loses $607,345 in Q3 20251
28.11.25Kane Biotech Inc.: Kane Biotech Announces Third Quarter 2025 Financial Results718WINNIPEG, Manitoba, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) ("Kane Biotech", "Kane" or the "Company") today announced its third quarter 2025 financial results. Third Quarter...
► Artikel lesen
27.11.25Kane Biotech Inc (2): Kane Biotech arranges $800,000 private placement1
27.11.25Kane Biotech Inc.: Kane Biotech Announces New Private Placement Offering2
04.11.25Kane Biotech Inc (2): Kane receives clinical, preclinical data for revyve3
17.09.25Kane Biotech Inc (2): Kane Biotech completes submission for wound cleanser1
16.09.25Kane Biotech Inc.: Kane Biotech Completes U.S. FDA 510(k) Submission for revyve Antimicrobial Wound Cleanser284WINNIPEG, Manitoba, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) ("Kane Biotech" or the "Company") today announces that it has completed a U.S. Food and Drug Administration ("FDA")...
► Artikel lesen
Weiter >>
28 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1